Rep. April McClain Delaney Sells Shares of Labcorp Holdings Inc. (NYSE:LH)

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Labcorp stock on August 6th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Wabtec (NYSE:WAB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Viking (NYSE:VIK) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Trimble (NASDAQ:TRMB) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Transdigm Group (NYSE:TDG) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Tractor Supply (NASDAQ:TSCO) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Middleby (NASDAQ:MIDD) on 8/25/2026.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of STERIS (NYSE:STE) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Somnigroup International (NYSE:SGI) on 8/25/2026.
• Sold $100,001 – $250,000 in shares of Signet Jewelers (NYSE:SIG) on 8/25/2026.

Labcorp Price Performance

Shares of NYSE LH traded up $4.40 during midday trading on Friday, hitting $311.36. The company had a trading volume of 809,927 shares, compared to its average volume of 635,612. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $341.80. The business has a 50-day simple moving average of $310.39 and a two-hundred day simple moving average of $281.94. The firm has a market capitalization of $25.25 billion, a price-to-earnings ratio of 25.75, a price-to-earnings-growth ratio of 1.74 and a beta of 0.88.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same period in the prior year, the business posted $4.35 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities research analysts anticipate that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 28th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is currently 23.82%.

Hedge Funds Weigh In On Labcorp

Hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC acquired a new stake in shares of Labcorp during the fourth quarter valued at $991,000. Integrated Wealth Concepts LLC lifted its holdings in Labcorp by 7.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 177 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Labcorp by 52.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock worth $82,353,000 after purchasing an additional 121,304 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Labcorp during the 2nd quarter worth about $5,873,000. Finally, First Trust Advisors LP grew its holdings in shares of Labcorp by 83.2% during the second quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company’s stock worth $22,588,000 after buying an additional 39,087 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Robert W. Baird set a $352.00 price target on Labcorp in a research note on Friday, July 31st. Mizuho set a $355.00 price objective on Labcorp in a research note on Monday, August 10th. Truist Financial upped their target price on Labcorp from $320.00 to $350.00 and gave the company a “buy” rating in a report on Friday, July 31st. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings raised Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Labcorp presently has an average rating of “Moderate Buy” and an average target price of $336.36.

Insider Activity

In other news, Director Kerrii Anderson sold 3,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the sale, the director owned 6,563 shares in the company, valued at $2,087,165.26. This trade represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn Kyle sold 92 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $26,329.48. Following the completion of the transaction, the executive vice president owned 3,904 shares of the company’s stock, valued at $1,117,285.76. The trade was a 2.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 8,919 shares of company stock valued at $2,826,593 in the last 90 days. Insiders own 0.84% of the company’s stock.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Labcorp

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.